From: Debates in allergy medicine: specific immunotherapy efficiency in children with atopic dermatitis
Authors | Year of research | Country | Study design | The number of patients (treatment/control) | Category of the patients (Age) | The type of allergen | Route of administration | The total duration of the study (in months) | Clinical efficacy (the opinion of the Clinician -C/patient-P) Treatment/control (in %) | Reference number |
---|---|---|---|---|---|---|---|---|---|---|
Petrova S.I. et al. | 2006 | Russia | RCT DB PC | 99 (28-SLIT/39-placebo/32-BT) | teenagers/adult | HDM | SLIT | NM | C(+) | 68 |
Improvement in the SLIT group | ||||||||||
Pajno G.B. et al. | 2007 | Italy | RCT DB PC | 56 (28/28) | children (5–16) | HDM | SLIT | 18 | C(+) | 60 |
Improvement in mild-moderate forms after 9 months of treatment. SCORAD was significant (P = .025) | ||||||||||
Di Rienzo V. et al. | 2014 | Italy | Multicentric RCT open, parallel-group study | NM | children (5–18) | HDM | SLIT | 18 | C(+) | 36 |
Effectively in children with AD | ||||||||||
Qin Y.E. et al. | 2014 | Chinese | RCT DB PC | 107 (58/49) | NM | HDM | SLIT | 12 | C(+) | 70 |
77.78/53.85 (P < 0.05) | ||||||||||
Cadario G. et al. | 2007 | Italy | pilot study | 86 (53 females and 33 males) | children/adults (3–60) | HDM | SLIT | 12 | C(+) | 16 |
SCORAD Improvement from score 43,3→23,7 Reduces the SCORAD |